Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eukaryotic translation initiation factor 2 alpha subunit (eIF2α) is the alpha subunit of the eIF2 protein complex, which plays a critical role in the initiation phase of eukaryotic protein synthesis. The eIF2 complex is a heterotrimer composed of three nonidentical subunits: alpha (EIF2S1), beta (EIF2S2), and gamma (EIF2S3). The activity of eIF2α is tightly regulated through phosphorylation at serine residue S51. Phosphorylation inhibits general translation initiation but allows selective translation of specific mRNAs involved in stress responses. Dysregulation can contribute to diseases such as diabetes and neuronal apoptosis. Salubrinal is an inhibitor that prevents dephosphorylation of phosphorylated eIF2α.
Inhibition of eIF2α dephosphorylation (Salubrinal)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic Translation Initiation Factor 2 Alpha Subunit (eIF2α).